Lupine Publishers | Open Access Journal of Oncology and Medicine (OAJOM)
Introduction
The association between cancer and thrombosis has been known for a long time, and the majority of the thromboembolic events associated with cancer are usually diagnosed after the cancer being identified [1]. However, a thromboembolic event may precede the identification of a cancer and maybe the first manifestation of the underlying malignancy [2]. Malignant cancers promote hypercoagulable state and increases the risk of thromboembolism. Carcinoma is the most common cause of ischemic stroke associated with malignancy [3] with lung cancers being the most common [1,4] while adenocarcinoma confers a higher risk of recurrent venous thromboembolism (VTE) [5]. We report a case of recurrent embolic strokes resistant to anticoagulation as the first manifestation of poorly differentiated carcinoma (PDC) of unknown etiology. It is the first case reported in the literature.
Discussion
Hypercoagulable state is a common finding in patients with malignancy due to the production of substances with procoagulant activity. Different mechanisms have been implicated in the cerebrovascular complications of cancer patients and includes the following: [6]
I. Cerebral infarction from nonbacterial thrombotic endocarditis (NBTE).
II. Thrombosis due to compression or infiltration of cerebral vessels by tumor or coagulopathy induced by chemotherapy.
III. Cerebral venous sinus thrombosis due to hypercoagulable state or chemotherapy.
IV. Cerebral infarction due to tumor emboli or septic thrombi.
V. Intracranial hemorrhage which is more common in patients with hematological malignancies.
Our patient presented with ischemic stokes involving multiple vascular territories. A complete workup for ischemic stroke was performed, including Brain MRI, TEE and cerebral angiogram that ruled out the presence of brain tumors, atherosclerosis, vasculitis, cardiac embolic source as well as sinus thrombosis. The results were in favor of embolic strokes. The physical examination did not reveal any signs of sepsis or infection. The conventional etiologies of stroke could not be identified. Despite appropriate therapeutic anticoagulation the patient had recurrent ischemic strokes. The commonest cause of stroke in cancer patients is embolic due to hypercoagulation [1,4]. Recent study showed that infarction in multiple vascular territories in stroke patients associated with cancer is significantly elevated (34%), compared to 15% of stroke patients not associated with cancer [5], so it is important to consider the existence of a concealed cancer in stroke patients with multiple vascular territories involvement and conventional mechanisms for stroke etiology not identified. A retrospective study showed that in patients with ischemic stroke associated with cancer, the cumulative rates of recurrent ischemic stroke were 7 % at 1 month, 15 % at 3 and 6 months [3]. In our case the patient experienced recurrent events within a two-week period and continued despite adequate anticoagulation. It is unclear whether initiation of aggressive cancer treatment may have improved patient outcome as the family opted for withdrawal of care. Further study on the early initiation of cancer therapy in malignancy-associated ischemic strokes even during the acute phase may be warranted.
Read More about Lupine Publishers
No comments:
Post a Comment